Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-1β Humanized
Monoclonal Antibody injection in Healthy Subjects. Pharmacokinetics, Pharmacodynamics and
Anti-drug antibody (ADA) data will be collected; Drug safety, tolerability and immunogenicity
for healthy subjects will be evaluated.